Buss and Arnolds discuss underscore persistent gaps between gout guideline recommendations and real-world practice.
News|Articles|November 3, 2026
Joint Ventures ACR 2026 Preview: 6 Abstracts Rheumatologists Should Watch
Author(s)Rihards Buss, MD, Jack Arnold, MBBS, MRCP, PhD
Fact checked by: Victoria Johnson
Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.
Advertisement
Advertisement
A recent episode of the Joint Ventures podcast previewed 6 abstracts for
Related to this article
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
Mease revisits the biggest PsA readouts from EULAR 2026: guselkumab, izokibep, GLP-1 combo therapy and more.
Baricitinib achieved glucocorticoid-free remission in 65% of patients with new-onset polymyalgia rheumatica at week 16, versus 17% with placebo.
Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.
A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.
The FDA approved tildrakizumab for adults with active psoriatic arthritis based on two phase 3 trials showing improved ACR20 response at week 24 vs placebo.
Advertisement
Advertisement